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Aims. A study was performed to determine areas of diagnostic discrepancy in the reporting of cases of soft tissue tumours referred
to a specialist sarcoma unit. This was to pinpoint common discrepancies and to determine their causes. Methods and Results.W e
compared the sarcoma unit’s histopathology reports with referring reports on 349 specimens from 277 patients with suspected or
proven soft tissue tumours in a one-year period. Conclusions. Diagnostic agreement was found in 256 of 349 cases (73.4%), with
minor diagnostic discrepancy in 55 cases (15.7%) and major discrepancy in 38 cases (10.9%). Benign/malignant discordances
accounted for only 5% of all discrepancies (5 cases). The most common discrepancies occurred in tumour classiﬁcation, including
diagnosis of gastrointestinal stromal tumour and leiomyosarcoma and the subtyping of spindle cell sarcomas, as well as in tumour
grading that could conceivably lead to changes in clinical management. Major diagnostic discrepancies leading to management
change occurred in a relatively select range of tumour groups, and almost all discrepancies occurred due to diﬀerences in
tumour interpretation between general or nonsoft tissue pathologists, and pathologists at the specialist unit. The ﬁndings support
guidelines by the National Institute for Health and Clinical Excellence that diagnostic review of soft tissue tumours should be
performed by specialist soft tissue pathologists.
Copyright © 2009 K. Thway and C. Fisher. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Soft tissue tumours are diagnostically challenging, with
histopathologicalcriteriathatareconstantlyevolving,partic-
ularly concerning ancillary investigations such as immuno-
histochemistryandmoleculargenetics.Muchofthediagnos-
tic challenge is due to their rarity: the United Kingdom has
anannualincidenceofabout2.5per100000population,and
the average general pathologist might encounter only one or
two sarcomas throughout the course of a year. The Royal
Marsden Hospital (RMH) is a tertiary cancer treatment cen-
tre which receives referrals regionally, nationally, and inter-
nationally. The Sarcoma Unit at RMH takes approximately
1200 new histopathology accessions per year (excluding
second opinion cases), of which about 350 are referral cases.
In line with hospital policy, all new patients with suspected
or proven soft tissue tumours have their histology reviewed
by a specialist soft tissue pathologist. By comparing Sarcoma
Unit and referring reports, diagnostic discrepancies were
established, their reasons evaluated, and diagnostic areas
especially prone to problems described. Previous studies
have focussed on diﬀerences between second opinion and
referring reports, including sarcoma second opinion cases
[1]. Second opinion cases are distinct from referrals, as they
are mostly sought by pathologists, with smaller numbers
requested by clinicians: these cases are usually rarer and
more diagnostically challenging to pathologists without
special interest in soft tissue. Referral cases are mainly those
diagnosed by the local pathologist, on which diagnosis the
patient is then referred to a specialist centre. These cases,
in the main, represent less diagnostic challenge than those
sent for second opinion. Histopathological peer reviews for
sarcoma diagnoses have been published by Presant et al. in
the South East of the United States [2], by Alvegard and Berg
for the Scandinavian Sarcoma Group [3], and by Harris et
al. in the North West of England [4], but no recent similar
audits for soft tissue tumours exist. A contemporary study
is pertinent, since there has been considerable evolution in
the methods and criteria used for diagnosis of soft tissue
tumours.2 Sarcoma
2.MaterialsandMethods
A retrospective audit was performed for patients referred to
a specialist soft tissue sarcoma unit with soft tissue tumours
over a one-year period. The record ﬁles within the Depart-
ment of Histopathology at the Royal Marsden Hospital
were examined for a period of 12 months from the 1st of
January to the 31st of December 2005. Patients were either
surgical or oncological referrals. Referrals to the surgical
unit were usually patients with a new histological diagnosis
after biopsy, or those with recurrent lesions referred for
further surgery. Patients were referred to the medical or
clinical oncology units for planning of (neo)adjuvant treat-
ment. All second opinion cases (including those sent for
pathologicalopinion,butwherethepatientwasnotreferred)
were excluded, as were cases without referring reports. All
cases included in the study were reviewed during the time
period assessed by one of the authors (C.F.), and any cases
requiring subsequent review were assessed by both authors.
Each referring report was compared with the subsequent
SarcomaUnit report fordiﬀerencesindiagnosisandgrading.
Grading was assigned according to the system by the French
Federation of Cancer Centres Sarcoma Group (FNCLCC)
[5, 6]. Grading categories were deﬁned as (1) not applicable,
(2) not done, (3) no diﬀerence in grade, (4) diﬀerence by one
grade, and (5) diﬀerence by two grades. For gastrointestinal
stromal tumour (GIST), assessment of potential biological
behaviour into low, intermediate, and high risk was also
compared as for grading. Tumours for which the referring
pathologist had identiﬁed tumour type, performed a mitotic
count and reported on the absence or amount of necrosis
but had not given a numerical grade, were retrospectively
graded on review and recorded as “graded.” Tumours for
whichthemitoticcounthadnotbeenperformed,orpresence
or absence of necrosis not indicated or where neither had
been done, were not retrospectively graded. Tumours which
the referring pathologist had assigned as low, intermediate,
and high grade were interpreted as grade 1, 2, and 3
respectively. Grading was deemed as “not applicable” in (1)
certain sarcomas considered routinely to display aggressive
or “high-grade” behaviour, (2) metastatic tumours, (3)
tumours not formally graded, such as dermatoﬁbrosarcoma
protuberans, (4) benign lesions, (5) if there was a diﬀerence
in diagnosis between the referring and specialist unit report,
makinggradingnoncomparable,or(6)therewasinsuﬃcient
material for grading.
Major discrepancies were deﬁned as those that could
lead to signiﬁcant change in clinical management, with
ensuing under- or overtreatment, and were divided into six
groups: (1) malignant → malignant (resulting in signiﬁcant
management change), (2) malignant → benign, (3) benign
→ malignant, (4) mesenchymal → nonmesenchymal, (5)
other (e.g., benign → benign, but resulting in signiﬁcant
management change), and (6) major grading discrepancies,
comprising tumours in which there was any interchange of
grade between grades 2-3 and grade 1 (as this could lead to
management change).
Minordiscrepanciesweredividedintothoseofdiagnosis,
classiﬁcation, or grading, but they were those in which the
discrepancy was not thought to provoke signiﬁcant manage-
ment change. Minor changes in which the discrepancy was
purelysemantic,orinSarcomaUnitreportsinwhichsubcat-
egorisation was chieﬂy for special or academic interest (e.g.,
the addition of a ﬁnding of myoﬁbroblastic diﬀerentiation
withinpleomorphicsarcoma),weredisregarded.Thereasons
for discrepancy were analysed, by further assessing reports
and reviewing slides where appropriate or possible, to look
for sources of error such as interpretation of morphology or
immunohistochemistry.
3. Results
In the 12-month period studied, there were 277 referral
patients with suitable material for auditing, with a total
of 349 specimens. Some patients had multiple specimens
assessedinthistimeperiod.Theseincludedpatientswhohad
repeatcorebiopsies,whohadinitialcorebiopsiesproceeding
later to incisional/open biopsies, or who had core biopsies
with subsequent resection specimens. Of the specimens,
199 were oncological referrals, and 150 were surgical. 203
specimens were from district general hospitals, 120 from
teaching hospitals, and 26 from overseas hospitals. 256 of
349 cases (73.4%) showed diagnostic agreement between
referringandSarcomaUnitreports.93cases(26.6%)showed
discrepancy between referring and Sarcoma Unit reports.
There was no correlation between incidence of discrepancy
and type of referring institution. 47 cases were oncological
referrals, and 46 were surgical. 38 of the 93 discrepant
cases were major discrepancies (10.9% of total or 40.9% of
discrepancies; see Table 1), and 55 were minor (15.7% of
total, or 59.1% of discrepancies; see Table 2).
Of the 38 major discrepancies, 17 cases were diagnosed
on resection material, 11 on excisional or incisional biopsies,
and ten on needle core biopsies. Of the six groups of
major discrepancy, the largest was malignant → malignant,
accounting for 15 cases (39.5% of discrepancies in this
group). Within this group, the most common discrepant
diagnosis was for GIST (seven cases; 18.4% of major
diagnosticdiscrepancies).Thenextlargestgroupwasgrading
discrepancies (nine cases), followed by mesenchymal →
nonmesenchymal discrepancy (seven cases), benign →
malignant (three cases), and malignant → benign and other
(each two cases).
Of the 55 minor discrepancies, 28 were resections, 15
were excision biopsies, and 12 needle core biopsies. Of these,
29(52.7%)werediagnosticdiﬀerences,18(32.7%)wereclas-
siﬁcation diﬀerences, and eight (14.5%) were diﬀerences in
grading.Somepatternsemergedinthetypesofdiscrepancies
encountered, and particular areas of emphasis are discussed
below.
4.GIST
Diagnoses were changed to leiomyosarcoma (three cases),
dediﬀerentiated liposarcoma (three cases), and Kaposi sar-
coma(onecase).Themainreasonfordiagnostic discrepancy
was misinterpretation of immunohistochemistry for CD117
(two cases each of leiomyosarcoma and dediﬀerentiatedSarcoma 3
Table 1: Major discrepancies.
(a) Malignant → Malignant









Atypical leiomyoma Endometrial stroma sarcoma 1
Rhabdomyosarcoma Ewing sarcoma 1
Liposarcoma, WD Liposarcoma, dediﬀerentiated 2
(b) Grading
PreviousGrade Final Grade Number of cases
Leiomyosarcoma, grade 3 Grade 1 1
Leiomyosarcoma, grade 2 Grade 1 3
Leiomyosarcoma, grade 1 Grade 2 5
(c) Mesenchymal → Nonmesenchymal
PreviousDiagnosis FinalDiagnosis Number ofcases
DSRCT Carcinoma/GCT 1
Granuloma ? Sarcoma Seminoma, metastatic 1
? Sarcoma GCT 1
? Sarcoma ? Melanoma Anaplastic carcinoma 1
?S a r c o m a D L B C L 1
Chondrosarcoma Metaplastic carcinoma 1
MPNST Melanoma, metastatic 1
(d) Benign → Malignant
PreviousDiagnosis FinalDiagnosis Number ofcases
Cellular neurothekeoma GIST 1
Leiomyoma Leiomyosarcoma 1
Lipoma Liposarcoma, WD 1
(e) Malignant → Benign





Liposarcoma, WD Lipoma 1
(f) Other
PreviousDiagnosis FinalDiagnosis Number ofcases
IMT Fibromatosis 1
Nodular fasciitis Fibromatosis 1
liposarcoma, and the case of Kaposi sarcoma), while two
cases were due to morphological misinterpretation. In two
cases of leiomyosarcoma, smooth muscle markers were
positive, but faint diﬀuse nonspeciﬁc staining for CD117 had
been interpreted as positive. In two cases of dediﬀerentiated
liposarcoma, similar faint CD117 staining was interpreted as
positive, in the absence of positivity for other markers. In
the other case, CD117 was correctly interpreted as negative,
but the diagnosis was based on morphology. In the case
of Kaposi sarcoma, diﬀuse CD34 positivity (in addition to
focal CD117 positivity) led to misinterpretation; subsequent
positivity for antibody to Human Herpesvirus 8 (HHV-
8) led to reclassiﬁcation of the tumour at Sarcoma Unit.
In addition, three cases were changed to GIST following
review (two leiomyosarcoma, one cellular neurothekeoma).
Although morphology of all cases was adequately described,
the two cases diagnosed as leiomyosarcomas, from the
stomach and peritoneum, respectively, showed focal SMA
positivity,whileCD117hadnotbeenperformed.Thecellular
neurothekeoma had been diagnosed on morphology alone,
without ancillary immunohistochemistry. Morphology was
not considered consistent with this on review.
5. Smooth MuscleTumours
Misinterpretation of cases as leiomyosarcoma accounted for
4/38 (10.5%) of major discrepancies, with two cases reclas-
siﬁed as GIST following review, and one case each reclassi-
ﬁed as alveolar rhabdomyosarcoma and malignant solitary
ﬁbrous tumour. The cases reclassiﬁed as GIST showed
characteristic morphology and diﬀuse CD117 positivity
on immunohistochemistry at Sarcoma Unit, as described
above. Alveolar rhabdomyosarcoma had been diagnosed as
leiomyosarcoma on the strength of diﬀuse desmin positivity,
although smooth muscle marker immunohistochemistry
had not been performed, and the morphology was incon-
sistent. The case reclassiﬁed as solitary ﬁbrous tumour orig-
inated from the broad ligament and had been diagnosed on
morphologyalone.Astocasesinitiallyreportedasnonmalig-
nant smooth muscle tumours, one case diagnosed as atypical
leiomyomawasreclassiﬁedaslow-gradeendometrialstromal
sarcoma (ESS). This showed focal SMA positivity, but on
review,typicalESSmorphologywasnoted,anddiﬀuseCD10
positivity. One case reported as leiomyoma on core biopsy
was reclassiﬁed as leiomyosarcoma on review: the occasional
atypiareportedbythereferringinstitutionwasinterpretedas
diﬀuse atypia at Sarcoma Unit.
6. Liposarcoma
Two cases were referred with diagnoses of well-diﬀerentiated
liposarcoma, changed to dediﬀerentiated liposarcoma fol-
lowingreview.Ofthese,oneshowedseveralfocioflow-grade
dediﬀerentiation. The other, originally diagnosed as the
sclerosing form of well-diﬀerentiated liposarcoma, showed,
on review, several low-power ﬁelds with atypical, moderately
cellular tumour consistent with dediﬀerentiation.
7. Myoﬁbroblastic Lesions
Only two myoﬁbroblastic lesions were present within the
major discrepancy group, and neither of these was mistaken
for frank sarcoma. Both (one case, from the abdominal4 Sarcoma
Table 2: Minor discrepancies.
(a) Diagnostic discrepancies
Previous Diagnosis Final Diagnosis Number ofcases
Leiomyosarcoma Pleomorphic sarcoma 4
Spindle cell sarcoma, myoﬁbroblastic diﬀerentiation 2
Myoﬁbrosarcoma 1
Myxoﬁbrosarcoma 1
Leiomyosarcoma, pleomorphic Spindle cell sarcoma 1
Rhabdomyosarcoma Pleomorphic sarcoma, myogenic diﬀerentiation 1
Pleomorphic sarcoma, smooth muscle diﬀerentiation 1
Liposarcoma, pleomorphic Myxoﬁbrosarcoma 2
Myxoid liposarcoma 1
Liposarcoma, dediﬀerentiated Spindle cell rhabdomyosarcoma 1
Synovial sarcoma SFT, malignant 1
Extraskeletal osteosarcoma Pleomorphic sarcoma 1
Chondrosarcoma Extraskeletal osteosarcoma with focal chondrosarcomatous areas 1
Mesenchymal chondrosarcoma Pleomorphic sarcoma 1
Epithelioid haemangioendothelioma Epithelioid haemangioma 1
Sarcoma NOS SFT 1
Spindle cell sarcoma Leiomyosarcoma 1
Pleomorphic sarcoma Myxoinﬂammatory ﬁbroblastic sarcoma 1
Spindle cell proliferation Fibromatosis 2
Fibrosarcoma, grade 1 1
IMT 1
Spindle cell proliferation, atypical Leiomyosarcoma, grade 1 1
Spindle cell sarcoma NOS 1
(b) Classiﬁcation discrepancies
PreviousDiagnosis Final Diagnosis Number of cases
Smoothmuscletumour,lowmalignantpotential Leiomyosarcoma, grade 2 1
Leiomyosarcoma Cutaneous leiomyosarcoma 1
Leiomyosarcoma, cutaneous Leiomyosarcoma (non-cutaneous) 1
Pleomorphic leiomyosarcoma Leiomyosarcoma 1
Uterine ﬁbroid Smooth muscle tumour of uncertain malignant potential 1
Leiomyosarcoma, grade 1 Atypical leiomyoma 1
Smooth muscle tumour of uncertain malignant potential 1
Rhabdomyosarcoma Pleomorphic sarcoma with myogenic diﬀerentiation 1
Pleomorphic rhabdomyosarcoma Embryonal rhabdomyosarcoma, anaplastic variant 1
Alveolar rhabdomyosarcoma 1
Pleomorphic sarcoma 1
Liposarcoma Myxoid-round cell liposarcoma, grade 2 1
PNET Primitive malignant tumour with rhabdomyosarcomatous and
neural diﬀerentiation
1
Endometrial stromal sarcoma, high grade Endometrial stromal sarcoma, low grade 1
Pleomorphic sarcoma, rhabdomyosarcomatous
diﬀerentiation Pleomorphic sarcoma, myoﬁbroblastic diﬀerentiation 1
? Sarcoma ? carcinoma Pleomorphic sarcoma 1
Synovial sarcoma 1
Pleomorphic sarcoma Myxoﬁbrosarcoma 1
(c) Grading discrepancies
Previous Grade Final Grade Number of cases
Leiomyosarcoma, grade 2 Grade 3 2
Pleomorphic liposarcoma, grade 3 Grade 2 3
Pleomorphic sarcoma, grade 3 Grade 2 2
GIST, high risk Intermediate risk 1Sarcoma 5
cavity, originally diagnosed as inﬂammatory myoﬁbroblastic
tumour, and one case, from the calf, diagnosed as nodular
fasciitis) were interpreted as ﬁbromatosis following review.
Both cases showed the typical sweeping fascicular mor-
phology of ﬁbromatosis, and error was probably due to
morphological unfamiliarity.
8. Nonmesenchymal Lesions
7/38 (18.4%) of major discrepancies were due to cases
referred as sarcoma or possible sarcoma and reclassiﬁed
at Sarcoma Unit as nonmesenchymal lesions. The cases
were almost all poorly diﬀerentiated neoplasms, with ﬁnal
diagnoses of one each of carcinoma, metaplastic carcinoma,
carcinoma/germ cell tumour, germ cell tumour, metastatic
seminoma, metastatic melanoma, and diﬀuse large B-cell
lymphoma.
9.Grading
One tumour was downgraded by two grades. Five tumours
were upgraded from grade 1 to 2, and three tumours were
d o w n g r a d e df r o mg r a d e2t o1 .A l lo ft h e s et u m o u r sw e r e
leiomyosarcomas.
10. Classiﬁcation
Seven of 18 classiﬁcation discrepancies involved smooth
muscle tumours. Four of these were malignant lesions and
comprised one case of pleomorphic leiomyosarcoma reclas-
siﬁed as leiomyosarcoma (NOS), one case of smooth muscle
tumouroflowmalignantpotentialreclassiﬁedasleiomyosar-
coma, grade 2, one case of cutaneous leiomyosarcoma reclas-
siﬁed as leiomyosarcoma (noncutaneous), and one case of
leiomyosarcoma reclassiﬁed as cutaneous leiomyosarcoma.
11. Discussion
The total discrepancy rate in this study was 26.6%. In
comparison, the Southeastern Cancer Study Group reported
a 28% disagreement rate between primary institutional
diagnosis and reviewer diagnosis [2]. The Scandinavian
SarcomaGroupreportedthat25%ofsarcomastheyreviewed
were reclassiﬁed, and that in 40% the grade was changed
[3]. The North West England peer review in 1991 showed a
discrepancy rate of approximately 35% [4] (disagreement in
subtype in 17% and change in diagnosis to nonsarcomatous
tumours in 18%), with an agreement rate of sarcoma
subtype of 53%, and the remaining cases accounting for
tumourswheresubtypecouldnotbefurtherspeciﬁed,where
classiﬁcation was only possible as “malignant tumour NOS,”
or where diagnosis could not be given. The 2001 audit of soft
tissue second opinion cases by Arbiser et al. showed major
discrepancy in 25% of cases and minor discrepancy in 7%
[1].
Interestingly, benign/malignant discrepancies only
accounted for a small number of total discrepancies in this
study. Most major discrepancies were due to diﬀerences of
opinion in tumour categorisation. This implies that major
discrepancies are due to unfamiliarity of pathologists with
certain tumours, which may be reﬂected in selection of
inappropriate immunopanels, rather than, more crudely,
missing frankly malignant or frankly benign morphological
features. As previously mentioned, certain patterns emerge,
with some neoplasms more prone to misdiagnosis than
others.
From the authors’ experience (unpublished observa-
tions), misinterpretation of lesions as GIST can occur
relatively frequently, with both benign tumours, such as
ﬁbromatosis, and malignant tumours being erroneously
diagnosed. Conversely, GIST is also often mistaken for other
tumours, particularly because of the range of immuno-
histochemical markers it can express, and the frequent
presence of diﬀuse positivity for CD34 and/or h-caldesmon
might sway the pathologist into presuming vascular, ﬁbrob-
lastic or smooth muscle diﬀerentiation. Misinterpretation
of immunostaining for CD117 however remains the main
reason for diagnostic error, both with other CD117-positive
tumours such as Kaposi sarcoma [7] and with nonspeciﬁc
weak background staining for this marker (and occasional
cytoplasmic positivity in myoﬁbroblastic lesions) [8]w h i c h
isoftenmistaken fordiﬀusepositivity. Useofnewerreagents,
such as DOG1 [9], and of mutational analysis, might be
expected to reduce this discrepancy. Positivity in tumours
with high numbers of mast cells may rarely cause confusion.
Owing to the common and eﬀective use of targeted therapy
with imatinib, GIST is high on the list of diﬀerential
diagnoses for abdominal and retroperitoneal tumours for
both clinicians and pathologists, whereas other tumours
in these sites, such as dediﬀerentiated liposarcoma, might
be less anticipated by nonsoft tissue physicians. Reasons
for confusing GIST with leiomyosarcoma are apparent: the
morphological appearances can be similar, as both are
spindle cell lesions with fascicular architectures and with
cells showing paranuclear vacuolation. There is also overlap
in smooth muscle marker expression: in addition to SMA
positivity, present focally in up to 47% of GISTs, diﬀuse,
strong positivity for h-caldesmon is seen in many.
Although well-diﬀerentiated and dediﬀerentiated
liposarcomas are opposite ends of one disease spectrum,
they may be diﬃcult to distinguish, and low-grade
dediﬀerentiation, which is thought to exhibit similar
biologic behaviour to that of its high-grade counterpart,
might on occasion be sparsely cellular [10]. Discrepancies
in categorisation between well-diﬀerentiated liposarcoma
and dediﬀerentiated liposarcoma, even if dediﬀerentiation is
low grade, were placed in the “major discrepancy” category,
as sclerosing well-diﬀerentiated liposarcoma is a grade 1
tumour with a low recurrence risk, whereas dediﬀerentiated
liposarcoma has a much greater risk of recurrence as well
as metastasis. Three cases of liposarcoma were previously
reported as GISTs, as described above. One case diagnosed
as lipoma was changed to well-diﬀerentiated liposarcoma
following Sarcoma Unit review. This was situated deeply
in the neck: features of spindle cell lipoma were not
noted, and although in a relatively unusual site, the lesion
showed the characteristic septate morphology with enlarged,6 Sarcoma
hyperchromatic spindle cells typical of well-diﬀerentiated
liposarcoma. One case diagnosed as well-diﬀerentiated
liposarcoma was considered lipoma with fat necrosis on
review. Fat necrosis can often confuse, and vacuolations
within macrophages are frequently mistaken for lipoblasts.
Germ cell tumours accounted for three of seven
nonmesenchymal lesions. They were all in abdominopel-
vic/retroperitoneal locations, emphasising that metastatic
germ cell tumour should be considered in the diﬀerential
diagnosis of poorly diﬀerentiated tumours arising in these
sites. In diﬀuse large B-cell lymphoma, the presence of
dispersed atypical cells, particularly within sclerotic stroma
that might itself contain enlarged, reactively atypical ﬁbrob-
lastic/myoﬁbroblastic spindle cells, often showing strong and
diﬀuseexpressionofSMA,canleadtoconfusionwithspindle
cell sarcoma. Although easily distinguished with pan-B-cell
markers, an index of suspicion for lymphoma is required.
Of the 29 minor diagnostic discrepancies (Table 2(a)),
pleomorphic sarcoma (so-called malignant ﬁbrous histio-
cytoma) accounted for the diagnosis that tumours were
most frequently changed to. Four cases were originally
diagnosed as leiomyosarcoma. On review, all showed focal
SMApositivity,ofteninsubplasmalemmaldistributions,and
were negative for desmin and h-caldesmon, consistent with
myoﬁbroblastic diﬀerentiation. Typical leiomyosarcomatous
morphology (intersecting fascicles of spindle cells, possibly
with blunt-ended nuclei and paranuclear vacuolations) was
absent in each case. Pleomorphic sarcoma was also initially
diagnosed as rhabdomyosarcoma (two cases), extraskeletal
osteosarcoma, and mesenchymal chondrosarcoma (one case
each).
Leiomyosarcoma/pleomorphic leiomyosarcoma was the
diagnosis most frequently changed following Sarcoma Unit
review (nine cases). The diﬀerences probably occurred
becausethetertiarycentrepathologistshadhigherthresholds
and stricter criteria for diagnosing leiomyosarcoma, includ-
ing strong and diﬀuse smooth muscle marker immunohis-
tochemistry, and categorisation as pleomorphic leiomyosar-
coma only when conventional leiomyosarcoma was present
in other areas of the tumour. Interpretation of tumoural
osteoid is another diﬃcult area, as is lipoblast identiﬁcation.
Vacuolated ﬁbroblasts present in myxoﬁbrosarcoma, and
foamy macrophages in fat necrosis are often interpreted as
lipoblasts, although both lack the nuclear indentation of the
latter. Most of these diagnostic distinctions are, arguably,
relatively academic: the majority of cases remain high-grade
sarcomas regardless of subcategorisation, and although there
might be minor prognostic diﬀerences based on subsequent
diagnosis, treatment would not diﬀer signiﬁcantly in most
cases.
44 of 68 gradable malignant soft tissue tumours with
suﬃcient material were given a Trojani grade by the referring
pathologists. Grading was not obtainable in 13 additional
cases, where there was insuﬃcient material, for example, a
verysmallamountoftissueinaneedlecorebiopsyortumour
accounting for only a small portion of material in the core.
25% of sarcomas were regraded, including ﬁve from grade
1t og r a d e s2 / 3a n df o u rf r o mg r a d e s2 / 3t og r a d e1 .T h i s
is of clinical signiﬁcance, as grade 1 sarcomas are in general
treated by excision, whereas grade 2 tumours are treated
more aggressively, including with adjuvant radiotherapy.
The availability of ancillary tests was not, as might
be expected, a cause of signiﬁcant discrepancies. Virtually
all common immunohistochemical markers for soft tissue
tumour diagnosis are routinely available within the labo-
ratories of district general and teaching hospitals, and no
diagnostic discrepancy was knowingly noted to occur due
to a department lacking a particular antibody. Similarly, no
discrepancy occurred because of a subsequent positive result
on molecular genetic analysis at RMH. In both major and
minor discrepancy groups, the majority of specimens were
excisions, that is, there was suﬃcient lesional material for
diagnosis. No diﬀerence in rate was noted between referrals
from district or teaching hospitals.
Almost all discrepancies therefore occurred due to diﬀer-
ences in interpretation, either of morphology or immuno-
histochemistry. Part of the challenge in soft tissue diagnosis
is maintaining a suitable rate of exposure to cases, and this of
course is diﬃcult for the majority of pathologists who do not
work at tertiary soft tissue or bone centres. Previous studies
in the North West of England hypothesised the incidence of
soft tissue sarcoma there as 18 per 106 person years, meaning
approximately 70 new cases per year in this region [11, 12].
Histopathologists specialising in just one or a few ﬁelds
are more likely to know and be able to categorise these in
detail than the generalist. A pathologist seeing a high volume
of similar cases also, through experience, might routinely
perform CD117 on all abdominal or retroperitoneal spindle
cell lesions. Similarly, when diagnosing pleomorphic or
spindle cell sarcoma without speciﬁc diﬀerentiation in these
locations, the soft tissue pathologist, knowing that many
s u c ht u m o u r sh e r er e p r e s e n td e d i ﬀerentiated liposarcoma,
would look for an adjacent well-diﬀerentiated component.
Although not signiﬁcantly noted in this study, other areas
in which there might be diﬃculty include unusual (e.g.,
myxoid) variants of typical lesions. A further issue is that a
pathologistworkinginareferralcentrealreadyhasa“referral
bias” or index of suspicion, that is, a case coming in is
alreadyﬂaggedasapotentialsarcoma,incontrasttoageneral
pathologist faced with one case within a general surgical
pathology workload.
TheGuidelinesforCancerServicesissuedbytheNational
Institute for Health and Clinical Excellence (NICE) in 2006
indicate that all soft tissue sarcomas should be either ﬁrst
reported or reviewed by a specialist soft tissue sarcoma
pathologist, who regularly reports soft tissue tumours as
a signiﬁcant component of their workload, takes part in
external quality assessment (EQA), and is a member of a
properly constituted sarcoma multidisciplinary team (MDT)
[13]. All patients with soft tissue tumours assessed in a
diagnostic clinic should have their pathology reported by
either a specialist soft tissue pathologist or a pathologist
nominated by the sarcoma MDT as part of the local
diagnostic referral pathway, who has formal links to a
specialist soft tissue pathologist. Commissioners should
fund a formal system for second opinions and review of
diﬃcultcases,includingtheuseofmolecularandcytogenetic
facilities.Sarcoma 7
This audit emphasises that speciﬁc groups of interpreta-
tive discrepancies in soft tissue tumours exist and suggests
that soft tissue tumours should be reported by or referred
to specialist soft tissue pathologists, as stated in the 2006
NICE guidelines. The study relates to a period before these
guidelines were in place.
12. Conclusions
The purpose of this audit was to pinpoint common discrep-
ancies in soft tissue tumour diagnosis and to ﬁnd causes for
these. Certain tumours were more liable to misinterpreta-
tion and included GIST, leiomyosarcoma, and pleomorphic
sarcoma. There was no signiﬁcant correlation between type
of referring institution and discrepancy rate, and diagnostic
disagreements were as frequent in resection material as
needle core biopsy. Almost all discrepancies occurred due to
interpretational diﬀerences, either of tumour morphology or
of immunophenotype. There was no case in which the dis-
crepancywasconclusivelyduetolackofavailableresourcesat
the referring institution, such as immunohistochemistry or
other ancillary investigations, and this suggests that reasons
fordisagreementareduetounfamiliarityindealingwithrare
cases or lack of awareness of certain site-speciﬁc tumours.
While the majority of tumours are accurately diagnosed
by referring pathologists, the discrepancy rate of almost
27% highlights that, as recommended by NICE guidelines,
it remains important to review the histopathology of all
patients referred to specialist soft tissue tumour centres.
Abbreviations
DLBCL: Diﬀuse large B-cell lymphoma
DSRCT: Desmoplastic small round cell tumour
GIST: Gastrointestinal stromal tumour
IMT: Inﬂammatory myoﬁbroblastic tumour
MPNST: Malignant peripheral nerve sheath tumour
NOS: Not otherwise speciﬁed
PNET: Primitive neuroectodermal tumour
RMS: Rhabdomyosarcoma
SFT: Solitary ﬁbrous tumour.
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